Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 40
Filtrar
1.
Rev Esp Quimioter ; 33(5): 358-368, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32693555

RESUMEN

OBJECTIVE: The aim of the study was to describe the epidemiological characteristics and factors related to outcome in Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA) healthcare-associated pneumonia (HCAP). METHODS: A 3-year prospective observational epidemiological case study of HCAP was conducted in seven Spanish hospitals. Microbiological and patient characteristics and outcomes were collected and classified by causative pathogen into 4 categories: "S. pneumoniae", "MRSA", "Others" and "Unknown". Patients were followed up 30 days after discharge. RESULTS: A total of 258 (84.6%) patients were enrolled (170 were men [65.9%]). Mean age was 72.4 years ± 15 years (95% CI [70.54-74.25]). The etiology of pneumonia was identified in 73 cases (28.3%): S. pneumoniae in 35 patients (13.6%), MRSA in 8 (3.1%), and other microorganisms in 30 patients (11.6%). Significant differences in rates of chronic obstructive pulmonary disease (p < 0.05), previous antibiotic treatment (p<0.05), other chronic respiratory diseases, inhaled corticosteroids (p <0.01), and lymphoma (p < 0.05) were observed among the four groups. Patients with MRSA pneumonia had received more previous antibiotic treatment (87.5%). Thirty-three (12.8%) patients died during hospitalisation; death in 27 (81.2%) was related to pneumonia. CONCLUSIONS: The etiology of HCAP was identified in only one quarter of patients, with S. pneumoniae being the most prevalent microorganism. Patients with chronic respiratory diseases more frequently presented HCAP due to MRSA than to S. pneumoniae. Death at hospital discharge was related in most cases to pneumonia.


Asunto(s)
Neumonía Asociada a la Atención Médica , Neumonía Estafilocócica , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Femenino , Neumonía Asociada a la Atención Médica/tratamiento farmacológico , Neumonía Asociada a la Atención Médica/epidemiología , Humanos , Masculino , Staphylococcus aureus Resistente a Meticilina , Persona de Mediana Edad , Neumonía Estafilocócica/tratamiento farmacológico , Neumonía Estafilocócica/epidemiología , Estudios Prospectivos , España/epidemiología , Streptococcus pneumoniae
3.
Rev Esp Quimioter ; 31(1): 78-100, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29480677

RESUMEN

Pseudomonas aeruginosa is characterized by a notable intrinsic resistance to antibiotics, mainly mediated by the expression of inducible chromosomic ß-lactamases and the production of constitutive or inducible efflux pumps. Apart from this intrinsic resistance, P. aeruginosa possess an extraordinary ability to develop resistance to nearly all available antimicrobials through selection of mutations. The progressive increase in resistance rates in P. aeruginosa has led to the emergence of strains which, based on their degree of resistance to common antibiotics, have been defined as multidrug resistant, extended-resistant and panresistant strains. These strains are increasingly disseminated worldwide, progressively complicating the treatment of P. aeruginosa infections. In this scenario, the objective of the present guidelines was to review and update published evidence for the treatment of patients with acute, invasive and severe infections caused by P. aeruginosa. To this end, mechanisms of intrinsic resistance, factors favoring development of resistance during antibiotic exposure, prevalence of resistance in Spain, classical and recently appeared new antibiotics active against P. aeruginosa, pharmacodynamic principles predicting efficacy, clinical experience with monotherapy and combination therapy, and principles for antibiotic treatment were reviewed to elaborate recommendations by the panel of experts for empirical and directed treatment of P. aeruginosa invasive infections.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Pseudomonas/tratamiento farmacológico , Consenso , Farmacorresistencia Bacteriana , Farmacorresistencia Bacteriana Múltiple , Quimioterapia , Humanos , Infecciones por Pseudomonas/epidemiología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , Sociedades Médicas , España/epidemiología
4.
Med. intensiva (Madr., Ed. impr.) ; 41(1): 3-11, ene.-feb. 2017. tab
Artículo en Inglés | IBECS | ID: ibc-160090

RESUMEN

OBJECTIVES: Infections caused by Candida species are common in critically ill patients and contribute to significant morbidity and mortality. The EPICO Project (Epico 1 and Epico 2.0 studies) recently used a Delphi approach to elaborate guidelines for the diagnosis and treatment of this condition in critically ill adult patients. We aimed to evaluate the impact of a multifaceted educational intervention based on the Epico 1 and Epico 2.0 recommendations. DESIGN: Specialists anonymously responded to two online surveys before and after a multifaceted educational intervention consisting of 60-min educational sessions, the distribution of slide kits and pocket guides with the recommendations, and an interactive virtual case presented at a teleconference and available for online consultation. SETTING: A total of 74 Spanish hospitals. PARTICIPANTS: Specialists of the Intensive Care Units in the participating hospitals. Variables of interest: Specialist knowledge and reported practices evaluated using a survey. The McNemar test was used to compare the responses in the pre- and post-intervention surveys. RESULTS: A total of 255 and 248 specialists completed both surveys, in both periods, respectively. The pre-intervention surveys showed many specialists to be unaware of the best approach for managing invasive candidiasis. After both educational interventions, specialist knowledge and reported practices were found to be more in line with nearly all the recommendations of the Epico 1 and Epico 2.0 guidelines, except as regards de-escalation from echinocandins to fluconazole in Candida glabrata infections (p = 0.055), and the duration of antifungal treatment in both candidemia and peritoneal candidiasis. CONCLUSIONS: This multifaceted educational intervention based on the Epico Project recommendations improved specialist knowledge of the management of invasive candidiasis in critically ill patients


OBJETIVOS: Las infecciones por Candida son frecuentes en los pacientes críticos y conllevan un incremento de la morbimortalidad. Nuestro objetivo es evaluar el impacto de una intervención educativa múltiple fundamentados en las recomendaciones de los proyectos basados en metodología Delphi Epico 1 y Epico 2.0. DISEÑO: Especialistas respondieron anónimamente 2 cuestionarios a través de Internet antes y después de una intervención educativa múltiple que consistió en: sesiones educativas de 60min, distribución de kits de diapositivas y guías de bolsillo, y un caso virtual interactivo presentado en una teleconferencia y disponible para su consulta a través de Internet. Ámbito: Setenta y cuatro hospitales españoles. PARTICIPANTES: Especialistas de las unidades de cuidados intensivos de los hospitales participantes. Variables de interés: Conocimientos y práctica clínica valorada a través de un cuestionario. El test de McNemar se empleó para comparar las respuestas entre los periodos pre y postintervención. RESULTADOS: Un total de 255 y 248 especialistas completaron ambos cuestionarios en los 2 periodos, respectivamente. Los cuestionarios preintervención mostraron que muchos especialistas desconocían el mejor tratamiento de la candidiasis invasiva. Después de las 2 intervenciones educativas, el conocimiento de los especialistas y las prácticas reportadas estaban más próximos a las recomendaciones de las guías Epico 1 y 2.0, excepto para el desescalado de equinocandinas a fluconazol en las infecciones por C. glabrata (p = 0,055) y en la duración del tratamiento antifúngico en la candidemia y en la peritonitis candidiásica. CONCLUSIONES: Esta intervención educativa múltiple basada en las recomendaciones del proyecto EPICO mejoró el conocimiento de los profesionales acerca del manejo de la candidiasis invasiva en el paciente crítico


Asunto(s)
Humanos , Candida/patogenicidad , Candidiasis/epidemiología , Candidemia/epidemiología , Cuidados Críticos/estadística & datos numéricos , Evaluación de Procesos y Resultados en Atención de Salud , Unidades de Cuidados Intensivos/estadística & datos numéricos , Mejoramiento de la Calidad/tendencias , Capacitación Profesional , Juegos de Video
5.
Med Intensiva ; 41(1): 3-11, 2017.
Artículo en Inglés, Español | MEDLINE | ID: mdl-27645566

RESUMEN

OBJECTIVES: Infections caused by Candida species are common in critically ill patients and contribute to significant morbidity and mortality. The EPICO Project (Epico 1 and Epico 2.0 studies) recently used a Delphi approach to elaborate guidelines for the diagnosis and treatment of this condition in critically ill adult patients. We aimed to evaluate the impact of a multifaceted educational intervention based on the Epico 1 and Epico 2.0 recommendations. DESIGN: Specialists anonymously responded to two online surveys before and after a multifaceted educational intervention consisting of 60-min educational sessions, the distribution of slide kits and pocket guides with the recommendations, and an interactive virtual case presented at a teleconference and available for online consultation. SETTING: A total of 74 Spanish hospitals. PARTICIPANTS: Specialists of the Intensive Care Units in the participating hospitals. VARIABLES OF INTEREST: Specialist knowledge and reported practices evaluated using a survey. The McNemar test was used to compare the responses in the pre- and post-intervention surveys. RESULTS: A total of 255 and 248 specialists completed both surveys, in both periods, respectively. The pre-intervention surveys showed many specialists to be unaware of the best approach for managing invasive candidiasis. After both educational interventions, specialist knowledge and reported practices were found to be more in line with nearly all the recommendations of the Epico 1 and Epico 2.0 guidelines, except as regards de-escalation from echinocandins to fluconazole in Candida glabrata infections (p=0.055), and the duration of antifungal treatment in both candidemia and peritoneal candidiasis. CONCLUSIONS: This multifaceted educational intervention based on the Epico Project recommendations improved specialist knowledge of the management of invasive candidiasis in critically ill patients.


Asunto(s)
Candidiasis Invasiva/tratamiento farmacológico , Competencia Clínica , Cuidados Críticos/métodos , Educación Médica Continua/métodos , Encuestas de Atención de la Salud , Juegos de Video , Adulto , Antifúngicos/uso terapéutico , Actitud del Personal de Salud , Biomarcadores , Candidiasis Invasiva/sangre , Candidiasis Invasiva/complicaciones , Manejo de la Enfermedad , Adhesión a Directriz , Humanos , Medicina , Neutropenia/complicaciones , Peritonitis/tratamiento farmacológico , Peritonitis/microbiología , Médicos/psicología , Guías de Práctica Clínica como Asunto , Evaluación de Programas y Proyectos de Salud , Insuficiencia Renal/complicaciones , España
6.
Rev Esp Quimioter ; 29(4): 230-8, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27580009

RESUMEN

The use of endovascular catheters is a routine practice in secondary and tertiary care level hospitals. Short peripheral catheters have been found to be associated with the risk of nosocomial bacteremia resulting in morbidity and mortality. Staphyloccus aureus is mostly associated with peripheral catheter insertion. This Consensus Document has been elaborated by a panel of experts of the Spanish Society of Cardiovascular Infections in cooperation with experts from the Spanish Society of Internal Medicine, Spanish Society of Chemotherapy and Spanish Society of Thoracic-Cardiovascular Surgery and aims at define and establish the norm for management of short duration peripheral vascular catheters. The document addresses the indications for insertion, catheter maintenance and registry, diagnosis and treatment of infection, indications for removal and stresses on continuous education as a driver for quality. Implementation of this norm will allow uniformity in usage thus minimizing the risk of infection and its complications.


Asunto(s)
Infecciones Relacionadas con Catéteres/prevención & control , Infecciones Relacionadas con Catéteres/terapia , Cateterismo Periférico/efectos adversos , Consenso , Adulto , Infecciones Relacionadas con Catéteres/diagnóstico , Cateterismo Periférico/métodos , Catéteres , Remoción de Dispositivos , Contaminación de Equipos , Medicina Basada en la Evidencia , Humanos
7.
Rev Esp Quimioter ; 29(5): 259-64, 2016 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-27608182

RESUMEN

OBJECTIVE: The clinical response to ertapenem in community-acquired pneumonia (CAP) at the setting of routine hospital practice has been scarcely evaluated. METHODS: We retrospectively compared CAP cases treated with ertapenem or with other standard antimicrobials (controls) at a tertiary 1,434-bed center from 2005 to 2014. RESULTS: Out of 6,145 patients hospitalized with CAP, 64 (1%) ertapenem-treated and 128 controls were studied (PSI IV-V 72%, mean age 73 years.). A significant higher proportion of bedridden patients (41% vs. 21%), residence in nursing homes (19% vs. 7%), previous use of antibiotics (39% vs. 29%) and necrotizing (13% vs. 1%) or complicated (36% vs. 19%) pneumonia, was observed in the ertapenem vs. non-ertapenem patients. Initial treatment with ertapenem was independently associated with an earlier resolution of signs of infection. In patients aged 65 or older the independent risks factors for mortality were: PSI score (7.0, 95%CI 1.8-27.7), bedridden status (4.6, 95%CI 1.1-20.9) and Health Care Associated Pneumonia (HCAP) (4.6, 95%CI 1.3-16.5). First-line treatment with ertapenem was an independent protector factor in this subgroup of patients (0.1, 95%CI 0.1-0.7). CONCLUSIONS: Ertapenem showed a superior clinical response in frail elderly patients with complicated community-acquired pneumonia, and it may be considered as a first-line therapeutic regimen in this setting.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Neumonía/tratamiento farmacológico , beta-Lactamas/uso terapéutico , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Infecciones Comunitarias Adquiridas/mortalidad , Comorbilidad , Ertapenem , Femenino , Anciano Frágil , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Casas de Salud , Neumonía/mortalidad , Estudios Retrospectivos , Factores de Riesgo
8.
Rev Esp Quimioter ; 27(3): 196-212, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25229375

RESUMEN

INTRODUCTION: Although there has been an improved management of Invasive Candidiasis in the last decade, still controversial issues remain, especially in different therapeutic critical care scenarios. OBJECTIVES: We sought to identify the core clinical knowledge and to achieve high agreement recommendations required to care for critically ill adult patients with Invasive Candidiasis for antifungal treatment in special situations and different scenarios. METHODS: Second Prospective Spanish survey reaching consensus by the Delphi technique, conducted anonymously by electronic e-mail in the first phase to 23 national multidisciplinary experts in invasive fungal infections from five national scientific societies including Intensivists, Anesthesiologists, Microbiologists, Pharmacologists and Infectious disease specialists, answering 30 questions prepared by a coordination group after a strict review of literature in the last five years. The educational objectives spanned four categories, including peritoneal candidiasis, immunocompromised patients, special situations and organ failures. The agreement among panelists in each item should be higher than 75% to be selected. In a second phase, after extracting recommendations from the selected items, a meeting was held with more than 60 specialists in a second round invited to validate the preselected recommendations. MEASUREMENTS AND MAIN RESULTS: In the first phase, 15 recommendations were preselected (peritoneal candidiasis (3), immunocompromised patients (6), special situations (3) and organ failures (3)). After the second round the following 13 were validated: Peritoneal candidiasis (3): Source control and early adequate antifungal treatment is mandatory; empirical antifungal treatment is recommended in secondary nosocomial peritonitis with Candida spp. colonization risk factors and in tertiary peritonitis. Immunocompromised patients (5): Consider hepatotoxicity and interactions before starting antifungal treatment with azoles in transplanted patients; treat candidemia in neutropenic adult patients with antifungal drugs at least 14 days after the first negative blood culture and until normalization of neutrophil count is achieved. Caspofungin, if needed, is the echinocandin with most scientific evidence to treat candidemia in neutropenic adult patients; Caspofungin is also the first choice drug to treat febrile candidemia; in neutropenic patients with candidemia remove catheter. Special situations (2): In moderate hepatocellular failure, patients with invasive candidiasis use echinocandins (preferably low doses of anidulafungin and caspofungin) and try to avoid azoles; in case of possible interactions review all of the drugs involved and preferably use Anidulafungin. Organ failures (3): Echinocandins are the safest antifungal drugs; reconsider the use of azoles in patients under renal replacement therapy; all of the echinocandins are accepted for the treatment of patients under continuous renal replacement therapy and do not require dosage adjustment. CONCLUSIONS: Treatment of Invasive Candidiasis in ICU patients requires a broad range of knowledge and skills as summarized in our recommendations. These recommendations may help to optimize the therapeutic management of these patients in special situations and different scenarios and improve their outcome based on the DELPHI methodology.


Asunto(s)
Antifúngicos/uso terapéutico , Candidiasis Invasiva/terapia , Cuidados Críticos/normas , Enfermedad Crítica/terapia , Adulto , Candidiasis Invasiva/complicaciones , Candidiasis Invasiva/tratamiento farmacológico , Técnica Delphi , Encuestas de Atención de la Salud , Humanos , Insuficiencia Multiorgánica/etiología , Insuficiencia Multiorgánica/terapia , Peritoneo/microbiología , Estudios Prospectivos , España
9.
Rev Esp Quimioter ; 27(1): 69-86, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24676248

RESUMEN

The incidence of community-acquired pneumonia (CAP) increases with age and is associated with an elevated morbimortality due to the physiological changes associated with aging and a greater presence of chronic disease. Taking into account the importance of this disease from an epidemiological and prognostic point of view, and the enormous heterogeneity described in the clinical management of the elderly, we believe a specific consensus document regarding this patient profile is necessary. The purpose of the present work was to perform a review of the evidence related to the risk factors for the etiology, the clinical presentation, the management and the treatment of CAP in elderly patients with the aim of elaborating a series of specific recommendations based on critical analysis of the literature. This document is the fruit of the collaboration of different specialists representing the Spanish Society of Emergency Medicine and Emergency Care (SEMES), the Spanish Society of Geriatrics and Gerontology (SEGG), the Spanish Society of Chemotherapy (SEQ), the Spanish Society of Internal Medicine (SEMI), the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) and the Spanish Society of Home Hospitalization (SEHAD).


Asunto(s)
Anciano , Antibacterianos/uso terapéutico , Manejo de Caso/normas , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Neumonía Bacteriana/tratamiento farmacológico , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Infecciones Comunitarias Adquiridas/etiología , Infecciones Comunitarias Adquiridas/microbiología , Farmacorresistencia Bacteriana , Anciano Frágil , Hospitalización , Humanos , Neumonía Bacteriana/etiología , Neumonía Bacteriana/microbiología , Pronóstico , Factores de Riesgo
10.
Rev. esp. anestesiol. reanim ; 60(7): e1-e18, ago.-sept. 2013.
Artículo en Español | IBECS | ID: ibc-115130

RESUMEN

Antecedentes. Aunque en la última década ha mejorado el manejo de la candidiasis invasiva, todavía persisten aspectos controvertidos, en especial por lo que respecta a la estrategia diagnóstica y terapéutica. Objetivos. Identificar los conocimientos clínicos esenciales y formular unas recomendaciones con la obtención de un alto grado de consenso, necesarias en la asistencia de pacientes adultos no neutropénicos en estado crítico con candidiasis invasiva. Métodos. Se preparó una encuesta prospectiva cuyo texto se redactó en español, y se obtuvo un consenso mediante técnica DELPHI (un método de reestructuración de un proceso de comunicación con el que se obtiene un grado de consenso de los especialistas sobre el problema planteado). En primer término, se envió de forma anónima por correo electrónico a 25 especialistas nacionales de diferentes disciplinas médicas, expertos en infecciones fúngicas invasivas, de 5 sociedades científicas nacionales, incluidos intensivistas, anestesistas, microbiólogos, farmacólogos e infectólogos, que respondieron a 47 preguntas preparadas por el grupo de coordinación, tras una revisión exhaustiva de los estudios publicados durante los 5 últimos años. Los objetivos educativos contemplaron 5 categorías: epidemiología, instrumentos diagnósticos, scores, estrategias terapéuticas y de desescalada. Para ser seleccionado, el grado de acuerdo alcanzado entre los expertos del panel en cada uno de los ítems debía superar el 75%. En segundo término, después de extraer las recomendaciones de los ítems seleccionados, se celebró una reunión presencial donde se invitó a participar en una segunda ronda a más de 80 especialistas y se les solicitó la validación de las recomendaciones preseleccionadas. ...(AU)


Background. Although there has been an improved management of invasive candidiasis in the last decade, controversial issues still remain, especially in the diagnostic and therapeutic approaches. Aims. We sought to identify the core clinical knowledge and to achieve high level agreement recommendations required to care for critically ill adult patients with invasive candidiasis. Methods. A prospective Spanish survey reaching consensus by the DELPHI technique was made. It was anonymously conducted by electronic mail in a first term to 25 national multidisciplinary experts in invasive fungal infections from five national scientific societies, including intensivists, anesthesiologists, microbiologists, pharmacologists and infectious diseases specialists, who answered to 47 questions prepared by a coordination group after a strict review of the literature in the last five years. The educational objectives spanned five categories, including epidemiology, diagnostic tools, prediction rules, and treatment and de-escalation approaches. The level of agreement achieved among the panel experts in each item should exceed 75% to be selected. In a second term, after extracting recommendations from the selected items, a face to face meeting was performed where more than 80 specialists in a second round were invited to validate the preselected recommendations. ...(AU)


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Candidiasis Invasiva/complicaciones , Candidiasis Invasiva/diagnóstico , Pruebas de Sensibilidad Microbiana/métodos , Sensibilidad y Especificidad , Fluconazol/uso terapéutico , Conocimientos, Actitudes y Práctica en Salud , Vías Clínicas/organización & administración , Vías Clínicas/normas , Candidiasis Invasiva/epidemiología , Candidiasis Invasiva/prevención & control , Encuestas Epidemiológicas/instrumentación , Encuestas Epidemiológicas/métodos , Encuesta Socioeconómica , Estudios Prospectivos
11.
Rev Esp Anestesiol Reanim ; 60(7): e1-e18, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23911095

RESUMEN

BACKGROUND: Although there has been an improved management of invasive candidiasis in the last decade, controversial issues still remain, especially in the diagnostic and therapeutic approaches. AIMS: We sought to identify the core clinical knowledge and to achieve high level agreement recommendations required to care for critically ill adult patients with invasive candidiasis. METHODS: A prospective Spanish survey reaching consensus by the DELPHI technique was made. It was anonymously conducted by electronic mail in a first term to 25 national multidisciplinary experts in invasive fungal infections from five national scientific societies, including intensivists, anesthesiologists, microbiologists, pharmacologists and infectious diseases specialists, who answered to 47 questions prepared by a coordination group after a strict review of the literature in the last five years. The educational objectives spanned five categories, including epidemiology, diagnostic tools, prediction rules, and treatment and de-escalation approaches. The level of agreement achieved among the panel experts in each item should exceed 75% to be selected. In a second term, after extracting recommendations from the selected items, a face to face meeting was performed where more than 80 specialists in a second round were invited to validate the preselected recommendations. RESULTS: In the first term, 20 recommendations were preselected (Epidemiology 4, Scores 3, Diagnostic tools 4, Treatment 6 and De-escalation approaches 3). After the second round, the following 12 were validated: (1) Epidemiology (2 recommendations): think about candidiasis in your Intensive Care Unit (ICU) and do not forget that non-Candida albicans-Candida species also exist. (2) Diagnostic tools (4 recommendations): blood cultures should be performed under suspicion every 2-3 days and, if positive, every 3 days until obtaining the first negative result. Obtain sterile fluid and tissue, if possible (direct examination of the sample is important). Use non-culture based methods as microbiological tools, whenever possible. Determination of antifungal susceptibility is mandatory. (3) Scores (1 recommendation): as screening tool, use the Candida Score and determine multicolonization in high risk patients. (4) Treatment (4 recommendations): start early. Choose echinocandins. Withdraw any central venous catheter. Fundoscopy is needed. (5) De-escalation (1 recommendation): only applied when knowing susceptibility determinations and after 3 days of clinical stability. The higher rate of agreement was achieved in the optimization of microbiological tools and the withdrawal of the catheter, whereas the lower rate corresponded to de-escalation therapy and the use of scores. CONCLUSIONS: The management of invasive candidiasis in ICU patients requires the application of a broad range of knowledge and skills that we summarize in our recommendations. These recommendations may help to identify the potential patients, standardize their global management and improve their outcomes, based on the DELPHI methodology.


Asunto(s)
Candidiasis Invasiva , Consenso , Cuidados Críticos/métodos , Enfermedad Crítica/terapia , Encuestas de Atención de la Salud , Adulto , Anestesiología/organización & administración , Candidiasis Invasiva/diagnóstico , Candidiasis Invasiva/tratamiento farmacológico , Candidiasis Invasiva/epidemiología , Cuidados Críticos/organización & administración , Técnica Delphi , Humanos , Infectología/organización & administración , Microbiología/organización & administración , Farmacología/organización & administración , Estudios Prospectivos , Sociedades Médicas , Sociedades Científicas , España , Encuestas y Cuestionarios
12.
Clin Microbiol Infect ; 19(2): 187-92, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22390624

RESUMEN

The number of elderly patients in the community with immunosuppressive conditions has increased progressively over recent decades. We sought to determine the incidence, causative organisms and outcome of community-acquired pneumonia (CAP) occurring in immunocompromised older patients. We prospectively compared cases of CAP in immunocompromised and non-immunocompromised patients admitted to five public hospitals in three Spanish regions. Of 320 cases studied, 115 (36%) occurred in immunocompromised patients, including: solid or hematological malignancy (97), corticosteroids or other immunosuppressive drugs (44), solid organ or stem cell transplant (five), and other conditions (eight). The etiology was established in 44% of immunocompromised patients vs. 32% of non-immunocompromised patients (p 0.03). Streptococcus pneumoniae was the most common causative organism in both groups (29% vs. 21%; p 0.08), followed by Legionella pneumophila (3% vs. 6%; p 0.01). Gram-negative bacilli were more frequent among immunocompromised patients (5% vs. 0.5%; p <0.01), particularly Pseudomonas aeruginosa (3% vs. 0%; p 0.04). Nocardiosis was only observed in immunocompromised patients (two cases). Bacteremia occurred similarly in the two groups. No significant differences were found with respect to ICU admission (8%, in both groups) or the length of stay (12.5 vs. 10.4 days). The early (<48 h) (3.5 vs. 0.5%; p 0.04) and overall case-fatality rates (12% vs. 3%; p <0.01) were higher in immunocompromised patients. In conclusion, a substantial number of older patients hospitalized for CAP are immunocompromised. Although relatively uncommon, CAP due to gram-negative bacilli, including P. aeruginosa, is more frequent among these patients. CAP occurring in immunocompromised patients causes significant morbidity and mortality.


Asunto(s)
Infecciones Comunitarias Adquiridas/epidemiología , Huésped Inmunocomprometido , Neumonía Bacteriana/epidemiología , Anciano , Anciano de 80 o más Años , Bacteriemia/epidemiología , Bacteriemia/etiología , Bacterias/clasificación , Bacterias/aislamiento & purificación , Infecciones Comunitarias Adquiridas/etiología , Femenino , Humanos , Incidencia , Masculino , Neumonía Bacteriana/complicaciones , Neumonía Bacteriana/etiología , Estudios Prospectivos , España/epidemiología , Análisis de Supervivencia , Resultado del Tratamiento
13.
Rev Esp Quimioter ; 24(1): 42-7, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21412669

RESUMEN

OBJECTIVES: We sought to evaluate the clinical use of linezolid for the treatment of neurosurgical infections. METHODS: Retrospective observational study of a cohort of hospitalized patients who received linezolid for a culture-positive neurosurgical infection from July 2004 to February 2009 in a tertiary hospital in Spain. RESULTS: Seventeen patients were included in the study. Main comorbidities among these patients included one or more of the following: subarachnoidal or intraventricular hemorrhage (n=8), solid neurological cancer (n=7), corticosteroids(n=9) and hydrocephalus (n=6). Eight patients underwent a craniotomy and fourteen patients had an external ventricular drainage (EVD) as predisposing factors for infection. Meningitis was the most common infection (11; 64.7%), followed by ventriculitis (4; 23.5%) and brain abscesses (2;11.8%). The main causative organisms were coagulase-negative Staphylococcus spp. (13; 76.5%). Linezolid was used as the initial therapy in 8 episodes, after therapy failure in 6 and for other reasons in 3. The oral route was used in 9 (52.9%) episodes; linezolid was initiated orally in 2 cases. The mean duration of treatment was 26.5 days (range 15-58). No adverse events were reported. Sixteen (94.1%) patients were considered cured.There was one recurrence. The mean length of hospital stay was 45.6 (range 15-112) days and the mean duration of follow-up was 7.2 (range 0.4-32) months. No related deaths occurred during active episodes. CONCLUSIONS: Linezolid was mainly indicated in post-neurosurgical EVD-associated infections due to coagulase-negative Staphylococcus spp. It was used as initial therapy in most cases. A high rate of clinical cure was observed and no related adverse events were reported. More than half of the patients were benefited by the advantages of the oral route of administration.


Asunto(s)
Acetamidas/uso terapéutico , Antibacterianos/uso terapéutico , Procedimientos Neuroquirúrgicos , Oxazolidinonas/uso terapéutico , Infección de la Herida Quirúrgica/tratamiento farmacológico , Acetamidas/efectos adversos , Adolescente , Adulto , Anciano , Antibacterianos/efectos adversos , Estudios de Cohortes , Craneotomía , Femenino , Humanos , Linezolid , Masculino , Persona de Mediana Edad , Oxazolidinonas/efectos adversos , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/microbiología , Estudios Retrospectivos , España , Infección de la Herida Quirúrgica/microbiología , Adulto Joven
16.
Rev. esp. quimioter ; 22(3): 151-172, sept. 2009. ilus, tab
Artículo en Español | IBECS | ID: ibc-76864

RESUMEN

Un número importante de pacientes con infección intraabdominaldesarrollan estados avanzados de la infeccióny la mortalidad es todavía superior al 20%. El fracaso esmultifactorial y se relaciona con el incremento de resistenciasbacterianas, el tratamiento empírico inapropiado, la mayorcomorbilidad de los pacientes y el mal control del foco de infección.Estas guías analizan cada uno de estos problemas yproponen medidas para evitar el fracaso, basadas en la mejorevidencia científica actual (AU)


A significant number of patients with abdominal infectiondevelop advanced stages of infection and mortalityis still above 20%. Failure is multifactorial and isassociated with an increase of bacterial resitance, inappropriateempirical treatment, a higher comorbidity of patientsand poor source control of infection. These guidelinesdiscuss each of these problems and propose measuresto avoid the failure based on the best current scientificevidence (AU)


Asunto(s)
Humanos , Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Abdomen , Complicaciones Posoperatorias/tratamiento farmacológico , Infección Hospitalaria/microbiología , Infecciones Bacterianas/complicaciones , Infecciones Bacterianas/diagnóstico
17.
Rev Esp Quimioter ; 22(3): 151-72, 2009 Sep.
Artículo en Español | MEDLINE | ID: mdl-19662549

RESUMEN

A significant number of patients with abdominal infection develop advanced stages of infection and mortality is still above 20%. Failure is multifactorial and is associated with an increase of bacterial resistance, inappropriate empirical treatment, a higher comorbidity of patients and poor source control of infection. These guidelines discuss each of these problems and propose measures to avoid the failure based on the best current scientific evidence.


Asunto(s)
Abdomen , Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/complicaciones , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/microbiología , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Humanos , Complicaciones Posoperatorias/tratamiento farmacológico , Complicaciones Posoperatorias/microbiología
18.
Rev. esp. quimioter ; 21(4): 234-258, dic. 2008. tab, graf
Artículo en Español | IBECS | ID: ibc-136537

RESUMEN

Las infecciones por Staphylococcus aureus resistente a meticilina (SARM) han experimentado importantes cambios en los últimos 5 años que condicionan la elección del tratamiento antibiótico: a) incremento de su frecuencia en el hospital y aparición de cepas de SARM adquiridas en la comunidad, sin ninguna relación con las de origen nosocomial y con un comportamiento clínico en cierto modo peculiar; b) progreso en la comprensión de los parámetros de farmacocinética/farmacodinamia (FC/FD) que rigen la eficacia de los antimicrobianos, incluyendo el reconocimiento de la importancia que tiene el valor de la concentración mínima inhibitoria (CMI) de vancomicina en el pronóstico de la infección por SARM tratada con glucopéptidos; c) la implementación en los laboratorios de microbiología de técnicas para la identificación rápida de SARM en muestras clínicas; d) clara evidencia de la pérdida de eficacia de vancomicina frente a SARM cuando la CMI es > 1 mg/ml, y e) la introducción en terapéutica de nuevos antibióticos activos frente a SARM (linezolid, daptomicina, tigeciclina). Ante esta situación, el desarrollo de guías de tratamiento para las infecciones habituales por SARM parece ser necesario para mejorar la eficacia y reducir la mortalidad (AU)


Infections due to methicillin-resistant Staphylococcus aureus (MRSA) have undergone important changes in the last five years that have influenced the choice of therapy: i) increase of their frequency in hospital-associated settings and, more recently, in community settings; ii) better knowledge of clinical implications of the pharmacokinetic and pharmacodynamic properties of vancomycin; iii) improvement of current standard methods for rapid detection of MRSA in clinical samples; iv) clear evidence that vancomycin is losing efficacy against MRSA with MIC > 1 μg/mL; and v) appearance of new antibiotics suitable for use in these infections (linezolid, daptomycin, tigecyclin). Under this situation guidelines for the treatment of common infections caused by MRSA appear to be necessary to improve the efficacy and reduce the mortality (AU)


Asunto(s)
Humanos , Staphylococcus aureus Resistente a Meticilina , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/epidemiología , Antibacterianos/uso terapéutico , Árboles de Decisión
19.
Rev Esp Quimioter ; 21(4): 234-58, 2008 Dec.
Artículo en Español | MEDLINE | ID: mdl-19031124

RESUMEN

Infections due to methicillin-resistant Staphylococcus aureus (MRSA) have undergone important changes in the last five years that have influenced the choice of therapy: i) increase of their frequency in hospital-associated settings and, more recently, in community settings; ii) better knowledge of clinical implications of the pharmacokinetic and pharmacodynamic properties of vancomycin; iii) improvement of current standard methods for rapid detection of MRSA in clinical samples; iv) clear evidence that vancomycin is losing efficacy against MRSA with MIC > 1 microg/mL; and v) appearance of new antibiotics suitable for use in these infections (linezolid, daptomycin, tigecyclin). Under this situation guidelines for the treatment of common infections caused by MRSA appear to be necessary to improve the efficacy and reduce the mortality.


Asunto(s)
Staphylococcus aureus Resistente a Meticilina , Infecciones Estafilocócicas/tratamiento farmacológico , Antibacterianos/uso terapéutico , Árboles de Decisión , Humanos , Infecciones Estafilocócicas/epidemiología
20.
Rev. esp. quimioter ; 21(2): 127-142, jun. 2008. tab
Artículo en Español | IBECS | ID: ibc-77582

RESUMEN

La relevancia que las micosis sistémicas han adquiridoen los pacientes no profundamente inmunodeprimidos, lasdificultades de tratamiento que presentan por el incrementode la especies de Candida no albicans y la necesidad dehacer un mejor uso y más racional de los nuevos antifúngicos(voriconazol, posaconazol, caspofungina, micafungina yanidulafungina) han reunido a un panel de expertos en enfermedadesinfecciosas en representación de la Sociedad Españolade Quimioterapia (SEQ), Sociedad Española de MedicinaInterna (SEMI) y Sociedad Española de Neumología yCirugía Torácica (SEPAR) para hacer unas recomendacionesbasadas en la evidencia científica buscando mejorar la efectividad (AU)


Because of the relevance that the systemic mycoses hasacquired in non-highly immunocompromised patients, thetreatment difficulties they have due to the increase of thenon-albicans Candida species and the need to have a betterand more rational use of the new antifungal agents (voriconazole,posaconazole, caspofungin, anidulafungin and micafungin),an experts' panel on infectious diseases in representationof the Spanish Society of Chemotherapy, SpanishSociety of Internal Medicine, and Spanish Society of Pneumologyand Thoracic Surgery has met in order to make a few recommendations based on the scientific evidence in aneffort to improve their efficiency (AU)


Asunto(s)
Humanos , Masculino , Femenino , Micosis/complicaciones , Micosis/etiología , Micosis/inmunología , Micosis/patología , Micosis/terapia , España/epidemiología , Antifúngicos/administración & dosificación , Antifúngicos/efectos adversos , Antifúngicos/normas , Antifúngicos/uso terapéutico , Infecciones/epidemiología , Infecciones/fisiopatología , Infecciones/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...